UNICYCIVE THERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Diluted
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$12.82 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-05-12
- UNICYCIVE THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$12.82M.
- UNICYCIVE THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$14.67M.
- UNICYCIVE THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$6.01M.
- UNICYCIVE THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-06-30 was -$6.45M.
- UNICYCIVE THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$26.55M.
- UNICYCIVE THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$37.82M.
- UNICYCIVE THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$31.41M.
- UNICYCIVE THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$18.06M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|---|---|
| 2026-03-31 | -$12.82M 10-Q · filed 2026-05-12 | -$27.49M derived: sum of 2 quarters · filed 2026-05-12 | -$33.50M derived: sum of 3 quarters · filed 2026-05-12 | -$39.95M derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2025-12-31 | -$14.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$20.68M derived: sum of 2 quarters · filed 2026-03-30 | -$27.13M derived: sum of 3 quarters · filed 2026-03-30 | -$26.55M 10-K · filed 2026-03-30 | ||
| 2025-09-30 | -$6.01M 10-Q · filed 2025-11-12 | -$12.46M derived: sum of 2 quarters · filed 2025-11-12 | -$11.89M 10-Q · filed 2025-11-12 | -$40.20M derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2025-06-30 | -$6.45M 10-Q · filed 2025-08-14 | -$5.88M 10-Q · filed 2025-08-14 | -$34.19M derived: sum of 3 quarters · filed 2026-05-12 | -$38.28M derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2025-03-31 | -$6.21M 10-Q · filed 2026-05-12 | -$27.74M derived: sum of 2 quarters · filed 2026-05-12 | -$31.84M derived: sum of 3 quarters · filed 2026-05-12 | -$45.60M derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | -$21.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$25.62M derived: sum of 2 quarters · filed 2026-03-30 | -$39.39M derived: sum of 3 quarters · filed 2026-03-30 | -$37.82M 10-K · filed 2026-03-30 | ||
| 2024-09-30 | -$4.10M 10-Q · filed 2025-11-12 | -$17.86M derived: sum of 2 quarters · filed 2025-11-12 | -$16.30M 10-Q · filed 2025-11-12 | -$46.83M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | -$13.77M 10-Q · filed 2025-08-14 | -$12.20M 10-Q · filed 2025-08-14 | -$42.74M derived: sum of 3 quarters · filed 2025-08-14 | -$47.14M derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | -$21.17M 10-Q · filed 2025-05-14 | -$28.97M derived: sum of 2 quarters · filed 2025-05-14 | -$33.37M derived: sum of 3 quarters · filed 2025-05-14 | -$37.81M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | -$7.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$12.20M derived: sum of 2 quarters · filed 2025-03-31 | -$16.64M derived: sum of 3 quarters · filed 2025-03-31 | -$31.41M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | -$4.41M 10-Q · filed 2024-11-13 | -$8.85M derived: sum of 2 quarters · filed 2024-11-13 | -$23.61M 10-Q · filed 2024-11-13 | -$28.94M derived: sum of 4 quarters · filed 2024-11-13 | ||
| 2023-06-30 | -$4.44M 10-Q · filed 2024-08-14 | -$81.00K 10-Q · filed 2023-08-14 | -$19.21M 10-Q · filed 2024-08-14 | $14.69M 10-Q · filed 2023-08-14 | -$24.54M derived: sum of 3 quarters · filed 2024-08-14 | -$30.09M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$14.77M 10-Q · filed 2024-05-13 | -$14.54M 10-Q · filed 2023-05-16 | -$20.09M derived: sum of 2 quarters · filed 2024-05-13 | -$25.65M derived: sum of 3 quarters · filed 2024-05-13 | -$22.02M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | -$5.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$10.88M derived: sum of 2 quarters · filed 2024-03-28 | -$7.25M derived: sum of 3 quarters · filed 2024-03-28 | -$18.06M 10-K · filed 2024-03-28 | ||
| 2022-09-30 | -$5.56M 10-Q · filed 2023-11-14 | -$1.92M derived: sum of 2 quarters · filed 2023-11-14 | -$12.73M 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | $3.64M 10-Q · filed 2023-08-14 | $7.17M 10-Q · filed 2023-08-14 | ||||
| 2022-03-31 | -$3.54M 10-Q · filed 2023-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |